ClinicalTrials.gg
RecruitingNCT06895499HB0043-HS-0-01Updated Jan 7, 2026

Efficacy, Safety, and Tolerability of HB0043 in Hidradenitis Suppurativa Patients.

A Phase 1/2 interventional study of HB0043 and HB0043 in Hidradenitis Suppurativa, sponsored by Shanghai Huaota Biopharmaceutical Co., Ltd.. Recruiting at 1 site in China. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-01-07.

Sponsored by Shanghai Huaota Biopharmaceutical Co., Ltd. · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Jan 2026, 9 months ago, but the record still lists the study as recruiting.
  • Started Mar 2025; still recruiting 1 year 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
15
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 22 studies in Hidradenitis Suppurativa with a site in China — 13 open to participants now, 17 under way, 2 of them phase 3. Hidradenitis Suppurativa · China.

Planned enrollment
17th of 18
15 · median 76
Started
2025
with 8 others
Phase 1/2
3 of 22
2 open now
Primary completion
2026-01
later than 2 of 16 live
Registered
8th of 22
by date
Lead sponsor
1 of 22
Shanghai Huaota Biopharmaceutical Co., Ltd.

Among the 22 studies in Hidradenitis Suppurativa with a site in China, this one is the 17th largest by planned enrollment of the 18 interventional ones that give a count, is one of 9 that started in 2025, is one of 3 in phase 1/2, reaches primary completion later than 2 of the 16 other live ones, and was the 8th registered.

Hidradenitis Suppurativa

285 studies on the registry are indexed under Hidradenitis Suppurativa; 88 are open to participants now.

Browse Hidradenitis Suppurativa studies →

Open to participants now

13 of the 22 studies in Hidradenitis Suppurativa with a site in China are open now. Recruiting first, the newest first:

7 more — sign in →

All 13 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 61 Hidradenitis Suppurativa studies recruiting now, 33 (54%) set no upper age limit and 17 (28%) stop at 75 or younger; 13 take children under 18; 12 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 22 studies in Hidradenitis Suppurativa with a site in China, or all of them as a file.
02

Study summary

The purpose of this study is to assess efficacy safety and tolerability of HB0043 in adult patients with moderate to severe HS.

Read the detailed description

The total duration of the study is 28 weeks and consists of: Screening (up to 4 weeks), Treatment Period (20 weeks) and Safety Follow-Up (treatment-free follow-up for 4 weeks).

Participants who prematurely discontinue study treatment are encouraged to remain in the study. Participants who do not wish to remain in the study will enter a 4-week Safety Follow-Up period.

03

Conditions studied

  • Hidradenitis Suppurativa
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 1. Understand the research procedure of this study and provide written ; 2. Male or female, age 18 years or greater; 3. Diagnosis of HS with a disease duration of at least 6 months before screening; 4. Moderate to severe HS, concurrently meeting the following three criteria:

    1. HS lesions in at least 2 distinct anatomic area;
    2. One of the HS lesions must be Hurley Stage II or Hurley Stage III;
    3. Total abscess and inflammatory nodule (AN) count of greater than or equal to 3; 5. Acceptance by the patient, of childbearing age, to use safe methods throughout the study, including six months of follow-up.

Exclusion criteria

Exclusion Criteria:

  • 1. Participants with known to HB0043 or any of its ; 2. Participant has a draining fistula count of ≥20 at the Screening Visit; 3. Presence of other active diseases except HS, including but not limited to psoriasis, psoriatic arthritis, rheumatoid arthritis, systemic lupus erythematosus, inflammatory bowel disease, and uveitis; 4. Participant has any other active skin disease or condition that may interfere with the assessment of hidradenitis suppurativa; 5. History of lymphoproliferative disorders or any known within five years prior to the Screening Visit (excluding treated and cured cutaneous squamous cell carcinoma, basal cell carcinoma, carcinoma uterine in situ, or intraductal breast cancer in situ); 6. History of recurrent or recent serious infection; 7. Participant has active tuberculosis (TB) or concurrent treatment for latent TB or evidence of virus (HBV) or virus (HCV) or (HIV) infection; 8. Pregnant or lactating women; 9. Any reason why, in the opinion of the investigator, the patient should not participate.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
15 participants (estimated)

Study arms

  • Experimental
    HB0043: Low dose

    Participants assigned to arm 1 will receive a low dose of HB0043 via intravenous infusion every two weeks starting from week 0. The dose of HB0043 will adjusted to high dose at weeks 10, and the frequency remains Q2W. The frequency will adjusted to Q4W from weeks16, the last administration is weeks 20.

    Drug: HB0043

  • Experimental
    HB0043: Medium dose

    Participants assigned to Arm 2 will receive a medium dose of HB0043 via intravenous infusion every two weeks, commencing at week 0, and then at weeks 16 and 20.

    Drug: HB0043

  • Experimental
    HB0043: High dose

    Participants assigned to Arm 3 will receive a high dose of HB0043 via intravenous infusion every two weeks, commencing at week 0, and then at weeks 16 and 20.

    Drug: HB0043

Interventions

06

What researchers measure

Primary outcomes

  1. Safety and Tolerability of HB0043 in Patients with Moderate to Severe HS

    The incidence rate, characteristics, relevance, and severity of treatment-emergent adverse events (TEAEs) experienced by subjects during the treatment period.

    Time frame: From randomization to end of study, assessed up to 24 weeks.

Secondary outcomes

  1. Percentage of participants achieving HiSCR

    Percentage of participants achieving HiSCR at Week 12 was reported. For this score participants were defined as achievers or non-achievers. The positive HiSCR score was defined as a greater than or equal to (\>=) 50% reduction in inflammatory lesion AN count (sum of abscesses and inflammatory nodules), and no increase in abscesses or draining fistulas in hidradenitis suppurativa compared with the lesions counted on visit 1 (baseline).

    Time frame: Week 16 and 24

  2. Change From Baseline in Inflammatory Lesion (Abscesses and Inflammatory Nodules) Count

    The sum of abscesses and inflammatory nodules was measured for each participant to assess change in inflammatory lesion counts.

    Time frame: Week 16 and 24

  3. Change From Baseline in the number of lesions

    The number of lesions refers to the total sum of abscesses, iInflammatory nodules, and draining fistulas count.

    Time frame: Week 16 and 24

  4. Percentage of Participants Achieving ≥ 30% Reduction and ≥ 1 Unit Reduction From Baseline in PGA-NRS

    PGA-NRS is evaluated based on worst skin pain in a 24-hour recall period (maximal daily pain), ranging from 0 (no skin pain) to 10 (skin pain as bad as you can imagine). The percentage of participants who achieved at least 30% reduction and at least 1 unit reduction from Baseline in the PGA-NRS.

    Time frame: Week 16 and 24

  5. Percentage of participants achieving HiSCR75

    HiSCR75 is defined as at least a 75% reduction from Baseline in the total abscess and inflammatory nodule \[AN\] count, with no increase from Baseline in abscess or draining tunnel count

    Time frame: Week 16 and 24

  6. Change in absolute score from Baseline in International Hidradenitis Suppurativa Severity Score System (IHS4)

    Change from baseline in IHS4. IHS4 score is calculated by the number of nodules (multiplied by 1) + the number of abscesses (multiplied by 2) + the number of draining tunnels (multiplied by 4). A total score of 3 or less signifies mild, 4-10 signifies moderate and 11 or higher signifies severe disease.

    Time frame: Week 16 and 24

  7. Serum HB0043 concentrations throughout the study

    Time frame: From randomization to end of study, assessed up to 24 weeks.

  8. Incidence of anti-HB0043 antibody positive response throughout the study

    Time frame: From randomization to end of study, assessed up to 24 weeks.

  9. Percentage of participants achieving HiSCR90

    HiSCR90 is defined as at least a 90% reduction from Baseline in the total abscess and inflammatory nodule \[AN\] count, with no increase from Baseline in abscess or draining tunnel count

    Time frame: Week 16 and 24

  10. Percentage of participants achieving HiSCR100

    HiSCR100 is defined as at least a 100% reduction from Baseline in the total abscess and inflammatory nodule \[AN\] count, with no increase from Baseline in abscess or draining tunnel count

    Time frame: Week 16 and 24

  11. Change of the most severe Patient's Global Assessment of Skin Pain (PGA Skin Pain) within the past 24 hours

    The change from baseline in the most severe PGA Skin Pain (NRS score) within the past 24 hours

    Time frame: Week 16 and 24

  12. Dermatology Life Quality Index (DLQI)

    Percentage of participants achieving a DLQI total reduction of ≥4 minimal clinically important difference among participants with a baseline DLQI ≥4. DLQI produces a numeric score that can range from 0 to 30. A higher score indicates greater health related quality of life impairment.

    Time frame: Week 16 and 24

  13. hange of Hidradenitis Suppurativa Area and Severity Index Revised (HASI-R)

    Change from baseline in HASI-R

    Time frame: Week 16 and 24

  14. Change of HIDRA score

    Change from baseline in HIDRA score

    Time frame: Week 16 and 24

  15. Long-term efficacy of sonelokimab: Hidradenitis Suppurativa Quality of Life (HiSQOL)

    Change from baseline in HiSQOL total score

    Time frame: Week 16 and 24

  16. Change of Numerical Rating Scale (NRS)

    Percentage of participants achieving a ≥3-unit reduction from baseline in the NRS

    Time frame: Week 16 and 24

  17. Pharmacodynamic indicators include but are not limited to IL-17 and IL-36.

    Time frame: From randomization to end of study, assessed up to 24 weeks.

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Mar 2025 (actual). Primary completion is estimated for Jan 2026, 10 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 7, 2025
First posted
Mar 26, 2025
StartActual
Mar 19, 2025
Primary completionEst.
Jan 30, 2026
CompletionEst.
Mar 30, 2026
Last update
Jan 7, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 7, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06895499
Lead sponsor
Shanghai Huaota Biopharmaceutical Co., Ltd.
Collaborators
Dermatology Hospital affiliated to Shandong First Medical University
Responsible party
Sponsor
First posted
Mar 26, 2025
Start date
Mar 19, 2025
Primary completion
Jan 30, 2026 (estimated)
Completion
Mar 30, 2026 (estimated)
Last update
Jan 7, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: HB0043

Start the discussion